Business Context and Reporting Period
This Form 8-K filing by Aerpio Pharmaceuticals, Inc. (ARPO) reports a material definitive agreement entered into on May 11, 2020. The filing concerns an amendment to a 2018 License Agreement with Gossamer Bio, Inc. (a wholly-owned subsidiary of Gossamer Bio, Inc.). The agreement grants Gossamer an exclusive, sublicensable license to develop and commercialize AKB-4924 (re-designated GB004) and related products worldwide.
Key Financial Metrics
- Upfront Payment: Gossamer made a one-time payment of $15.0 million to Aerpio on the effective date of the Amendment.
- Approval Milestones: Aerpio is eligible to receive up to $40.0 million in milestone payments related to indications in ulcerative colitis and Crohn's disease.
- Sales Milestones: Aerpio is eligible to receive up to $50.0 million in sales milestone payments.
- Royalties: Tiered royalties on sales of licensed products at percentages ranging from the low to mid single digits, subject to customary reductions.
- Alternative Consideration: Under certain circumstances, Aerpio may elect to receive 20% of payments received by Gossamer and its stockholders in connection with a sublicense or change of control, in lieu of standard milestones and royalties.
The filing text does not provide clear values for total revenue, net profit, operating cash flow, gross margins, total debt, or current liquidity positions as this is a current report on a specific event rather than a periodic financial statement.
Material Changes Versus Prior Period
The Amendment modified certain economic terms contained in the original License Agreement dated June 24, 2018. The summary of economic terms in this filing supersedes the description provided in the Company's Form 8-K filed on June 25, 2018. All other terms of the original Agreement remain unchanged.
Guidance, Outlook, and Risks
Management Commentary: The Company announced the entry into the Amendment via a press release on May 12, 2020. The agreement secures immediate cash inflow and potential future upside through milestones and royalties for the GB004 asset.
Risks and Contingencies:
- Future payments are contingent upon regulatory approvals and sales performance.
- The alternative 20% payment option is subject to specific conditions regarding sublicenses or change of control transactions.
- Royalty rates are subject to customary reductions.
- Certain confidential portions of the Amendment exhibit have been omitted.
Investor Verification Checklist
- Verify the receipt of the $15.0 million upfront payment in the Company's cash balance.
- Review the full text of Amendment No. 1 (Exhibit 10.1) to understand specific conditions for the 20% alternative payment option.
- Monitor clinical trial progress for GB004 in ulcerative colitis and Crohn's disease to assess the likelihood of triggering the $40.0 million in approval milestones.
- Confirm the re-designation of AKB-4924 to GB004 in regulatory filings.